ArticleFrontiers in oncology2026
HBV reactivation in HCC patients following TACE: risk factors, antiviral therapy impact, and survival analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) reactivation after transcatheter Arterial Chemoembolization (TACE) can lead to severe complications and affect prognosis. Current research on HBV reactivation following TACE is limited and inconsistent. Long-term prognostic data on antiviral therapy (AVT) in patients undergoing TACE are also scarce. Purpose: This study aimed to evaluate the risk factors for HBV reactivation in hepatitis B surface antigen (HBsAg) positive Hepatocellular carcinoma (HCC) patients following TACE and the impact of prophylactic AVT on HBV reactivation and survival outcomes. Patients and methods: This retrospective study included HBsAg-positive, treatment-naive HCC patients who underwent TACE between December 2020 and December 2024. Patient baseline characteristics, TACE procedures, and follow-up data were collected. HBV reactivation was defined as a ≥2 log IU/mL increase in HBV DNA levels from baseline or HBsAg seroconversion. Prophylactic AVT was defined as anti-HBV drug administration before or during TACE, continued throughout follow-up. Survival outcomes were assessed using the Kaplan-Meier method, log-rank test and Cox proportional hazards regression analyses. Results: A total of 168 patients were enrolled. HBV reactivation occurred in 32 patients (19.0%). Multivariate analysis identified the absence of prophylactic AVT (odds ratio [OR] 3.56, 95% CI 1.55-8.18, P = 0.003) and chemotherapeutic agents (>2 agents) (OR 2.79, 95% CI 1.09-7.14, P = 0.032) as independent risk factors for HBV reactivation. Unadjusted Kaplan-Meier analysis showed that patients without HBV reactivation had significantly better OS (P = 0.036). Multivariable Cox proportional hazards regression analysis confirmed that HBV reactivation (hazard ratio [HR]=1.43, 95%CI:0.90-2.28, P = 0.047) and macrovascular invasion (HR = 1.69, 95%CI:1.14-2.51, P = 0.017) were independent predictors of poor OS, whereas prophylactic AVT was not significantly associated with OS (HR = 0.75, 95%CI:0.50-1.14, P = 0.182). Conclusion: In HBsAg-positive HCC patients undergoing TACE, the absence of prophylactic AVT and chemotherapeutic agents (>2 agents) are significant risk factors for HBV reactivation. HBV reactivation and macrovascular invasion are independent predictors of poor OS, while prophylactic AVT shows no significant association with OS. These findings provide real-world evidence for optimizing the clinical management of HBV-related HCC patients undergoing TACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.